









Markets
/
Stocks
/
nasdaq-akba
/

Akebia Therapeutics Inc

AKBA

1.315USD

-0.075-5.40%

Market hours （ET）Quotes delayed by 15 min

24.05MMarket Cap

LossP/E TTM



Akebia Therapeutics Inc

1.315

-0.075-5.40%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Akebia Therapeutics Inc

Currency: USD Updated: 2026-03-27

Key Insights

Akebia Therapeutics Inc's fundamentals are relatively healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 74 out of 157 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Strong Buy, with the highest price target at 4.40.In the medium term, the stock price is expected to trend down.The company has been performing well in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Akebia Therapeutics Inc's Score

Industry at a Glance

Industry Ranking

74 / 157

Overall Ranking

186 / 4542

Industry

Pharmaceuticals

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Negative

Akebia Therapeutics Inc Highlights

StrengthsRisks

Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with two commercial products for patients impacted by kidney disease. The Company is focused on developing and commercializing therapeutics. Its two preclinical development candidates are AKB-9090 and AKB-10108. The Company’s portfolio and hypoxia-inducible factor (HIF)-based commercialized products include Auryxia (ferric citrate) and Vafseo. Auryxia (ferric citrate) is an orally administered medicine approved and marketed in the United States for two indications: the control of serum phosphorus levels in adult patients with dialysis dependent chronic kidney disease (DD-CKD), and the treatment of iron deficiency anemia (IDA), in adult patients with non-dialysis-dependent chronic kidney disease (NDD-CKD). Vafseo, an oral HIF prolyl hydroxylase (HIF-PH), inhibitor. It utilizes third parties for the commercial distribution of Auryxia, including wholesale distributors and certain specialty pharmacy providers.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 21.36% year-on-year.

Undervalued

The company’s latest PE is -64.49, at a low 3-year percentile range.

Institutional Buying

The latest institutional holdings are 132.23M shares, increasing 1.10% quarter-over-quarter.

Held by Joel Greenblatt

Star Investor Joel Greenblatt holds 15.97K shares of this stock.

Analyst Rating

Based on 5 analysts

Strong Buy

Current Rating

4.400

Target Price

+216.55%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-03-27

The current financial score of Akebia Therapeutics Inc is 7.31, ranking 114 out of 157 in the Pharmaceuticals industry. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 57.62M, representing a year-over-year increase of 23.93%, while its net profit experienced a year-over-year increase of 46.31%.

Score

Industry at a Glance

Previous score

7.31

Change



Financials

7.95

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

4.56

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

6.81

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.23

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Akebia Therapeutics Inc's Company Valuation

Currency: USD Updated: 2026-03-27

The current valuation score of Akebia Therapeutics Inc is 7.76, ranking 47 out of 157 in the Pharmaceuticals industry. Its current P/E ratio is -64.49, which is -98.31% below the recent high of -1.09 and -12.69% above the recent low of -72.67.

Score

Industry at a Glance

Previous score

7.76

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 74/157

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-03-27

The current earnings forecast score of Akebia Therapeutics Inc is 9.20, ranking 3 out of 157 in the Pharmaceuticals industry. The average price target is 5.00, with a high of 6.00 and a low of 5.00.

Score

Industry at a Glance

Previous score

9.20

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 5 analysts

Strong Buy

Current Rating

4.400

Target Price

+216.55%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

174

Total

Median

Average

Company name

Ratings

Analysts

Akebia Therapeutics Inc

AKBA

Biogen Inc

BIIB

Amgen Inc

AMGN

Eli Lilly and Co

LLY

Vertex Pharmaceuticals Inc

VRTX

Gilead Sciences Inc

GILD

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-03-27

The current price momentum score of Akebia Therapeutics Inc is 6.72, ranking 73 out of 157 in the Pharmaceuticals industry. Currently, the stock price is trading between the resistance level at 1.54 and the support level at 1.16, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.94

Change

-0.22

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(4)

Neutral(2)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

-0.007

Neutral

RSI(14)

46.341

Neutral

STOCH(KDJ)(9,3,3)

17.339

Sell

ATR(14)

0.074

High Vlolatility

CCI(14)

-113.708

Sell

Williams %R

91.667

Oversold

TRIX(12,20)

0.340

Sell

StochRSI(14)

0.000

Sell

Moving Average

Sell(6)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MA5

1.376

Sell

MA10

1.416

Sell

MA20

1.367

Sell

MA50

1.358

Sell

MA100

1.502

Sell

MA200

2.376

Sell

Institutional Confidence

Currency: USD Updated: 2026-03-27

The current institutional shareholding score of Akebia Therapeutics Inc is 3.00, ranking 93 out of 157 in the Pharmaceuticals industry. The latest institutional shareholding proportion is 46.40%, representing a quarter-over-quarter increase of 0.03%. The largest institutional shareholder is The Vanguard, holding a total of 15.95M shares, representing 5.95% of shares outstanding, with 23.26% increase in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

BlackRock Institutional Trust Company, N.A.

16.72M

+0.85%

The Vanguard Group, Inc.

Star Investors

15.48M

+5.94%

State Street Investment Management (US)

11.84M

+48.11%

Geode Capital Management, L.L.C.

6.18M

+1.82%

Alerce Investment Management, L.P.

5.75M

Satter Muneer A

5.75M

Citadel Advisors LLC

3.19M

+37.48%

Renaissance Technologies LLC

Star Investors

3.95M

-5.76%

Qube Research & Technologies Ltd

3.21M

+87.00%

Risk Assessment

Currency: USD Updated: 2026-03-27

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Pharmaceuticals domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Akebia Therapeutics Inc is 3.50, ranking 102 out of 157 in the Pharmaceuticals industry. The company's beta value is 0.38. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. Akebia Therapeutics Inc’s latest ESG disclosure leads the Pharmaceuticals industry, indicating outstanding, compliant performance across environmental management, social responsibility, and governance, which may help mitigate overall risk.